Return Peptide Library
PGN-EDO51
FLevel 1 evidencePGN-EDO51
Other/Research
Basic Information
Categories
Cell-penetrating peptide-PMO conjugates
Overview
PepGen investigational peptide-PMO conjugate for exon 51 skipping in Duchenne muscular dystrophy: Phase I results from year 2024 showed lower-than-expected exon-skipping efficiency, leading to discontinuation.
Efficacy Rating
Terminated, Duchenne Muscular Dystrophy, Exon Skipping
Evidence Level
F
Evidence Type
No data available
Confidence
No data available
China Regulatory Status
Cosmetic Ingredient Directory
No data available
Food/Supplements
No data available
Medicine
No data available
Similar Peptide Recommendations
Disclaimer
The content on this platform is for educational and informational purposes only and does not constitute medical advice, formulation guidance, or a guarantee of regulatory compliance. All efficacy claims are labeled with their evidence level; please consult a professional before making any decisions.